The Costs and Valuation of Health Impacts of Measles and Rubella Risk Management Policies
- 5 August 2015
- journal article
- Published by Wiley in Risk Analysis
- Vol. 36 (7), 1357-1382
- https://doi.org/10.1111/risa.12459
Abstract
National and global health policymakers require good information about the costs and benefits of their investments in measles and rubella immunization programs. Building on our review of the existing measles and rubella health economics literature, we develop inputs for use in regional and global models of the expected future benefits and costs of vaccination, treatment, surveillance, and other global coordination activities. Given diversity in the world and limited data, we characterize the costs for countries according to the 2013 World Bank income levels using 2013 U.S. dollars (2013$US). We estimate that routine immunization and supplemental immunization activities will cost governments and donors over 2013$US 2.3 billion per year for the foreseeable future, with high-income countries accounting for 55% of the costs, to vaccinate global birth cohorts of approximately 134 million surviving infants and to protect the global population of over 7 billion people. We find significantly higher costs and health consequences of measles or rubella disease than with vaccine use, with the expected disability-adjusted life year (DALY) loss for case of disease generally at least 100 times the loss per vaccine dose. To support estimates of the economic benefits of investments in measles and/or rubella elimination or control, we characterize the probabilities of various sequelae of measles and rubella infections and vaccine adverse events, the DALY inputs for health outcomes, and the associated treatment costs. Managing measles and rubella to achieve the existing and future regional measles and rubella goals and the objectives of the Global Vaccine Action Plan will require an ongoing commitment of financial resources that will prevent adverse health outcomes and save the associated treatment costs.Keywords
Funding Information
- Centers for Disease Control and Prevention (U66IP000519)
- World Health Organization (200470477 APW)
This publication has 99 references indexed in Scilit:
- Measles Elimination Efforts and 2008–2011 Outbreak, FranceEmerging Infectious Diseases, 2013
- Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance dataThe Lancet, 2012
- The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective studyBMC Health Services Research, 2011
- Rubella Vaccination of Unknowingly Pregnant Women During Mass Campaigns for Rubella and Congenital Rubella Syndrome Elimination, The Americas 2001-2008The Journal of Infectious Diseases, 2011
- Replacing the measles ten-dose vaccine presentation with the single-dose presentation in ThailandVaccine, 2011
- Health Care-Associated Measles Outbreak in the United States After an Importation: Challenges and Economic ImpactThe Journal of Infectious Diseases, 2011
- Single versus multi-dose vaccine vials: An economic computational modelVaccine, 2010
- Health burden and economic impact of measles-related hospitalizations in Italy in 2002–2003BMC Public Health, 2007
- Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-BissauBMJ, 2006
- Epidemiology of subacute sclerosing panencephalitisThe Journal of Pediatrics, 1979